Disseminated Mycobacterium Avium Complex
On this page
Direct answer
High remittent fever with drenching night sweats, weight loss, diarrhoea, anaemia and hepatosplenomegaly at a CD4 count under 50 is disseminated Mycobacterium avium complex (MAC, also called MAI) disease — infection from environmental mycobacteria in water and soil, not spread person to person. Diagnosis rests on blood cultures or identification of the organism in bone marrow or tissue, because the picture mimics disseminated tuberculosis and lymphoma; treatment is clarithromycin or azithromycin plus ethambutol, with rifabutin considered, continued for at least twelve months and until the CD4 count is above 100 on ART. Azithromycin prophylaxis once weekly when the CD4 falls under 50, after TB has been excluded, is the classical preventive step.
What you must remember
- Setting: almost exclusively below CD4 50, typically 20-30; MAC (M. avium and M. intracellulare) are non-tuberculous mycobacteria acquired from soil and water, with no person-to-person transmission — contrast tuberculosis.
- Clinical picture: persistent high fever with steep swings and drenching sweats, weight loss, abdominal pain and chronic watery diarrhoea, generalised lymphadenopathy and striking hepatosplenomegaly; pancytopenia from marrow involvement and a raised alkaline phosphatase from hepatic infiltration are the laboratory signatures.
- Diagnosis: mycobacterial blood cultures using lysis-centrifugation or isolator-type systems; AFB smear and culture of bone marrow, lymph node or liver; the organism is a slow grower, so preliminary reports take weeks — treatment is often started on clinical grounds in the appropriate host.
- Treatment: clarithromycin 500 mg twice daily (or azithromycin) plus ethambutol 15 mg/kg daily as the backbone, with rifabutin 300 mg daily considered for added efficacy; monotherapy is forbidden because clarithromycin resistance emerges rapidly; amikacin or moxifloxacin may be added in severe disease.
- Duration: at least twelve months and until the CD4 count has been above 100 for six months on ART; unlike tuberculosis, there is no fixed short-course and no phase intensification.
- Primary prophylaxis: azithromycin 1,200 mg once weekly (clarithromycin twice daily as the alternative) when the CD4 count is under 50, once active disease including TB has been excluded; discontinue when the CD4 exceeds 100 for three months on ART.
- In India the practical issue is tuberculosis-first: disseminated TB is far more common, so MAC is suspected when cultures and molecular tests for M. tuberculosis are negative, the smear shows non-tuberculous morphology, or disease recurs despite adequate TB therapy.
- Immune reconstitution: focal MAC lymphadenitis or abscesses can flare after ART starts — localised IRIS managed with drainage or steroids while continuing both therapies.
How to work through a suspected case
A 38-year-old man on interrupted ART presents with six weeks of daily fevers peaking at 39.5 degrees, soaked bed sheets, an eight-kilogram weight loss and bulky cervical nodes; CD4 count is 24, haemoglobin 7.5 g/dL, alkaline phosphatase three-fold raised. Step one is the honest differential for "disseminated syndrome at CD4 24" in India: disseminated tuberculosis tops the list, then MAC, lymphoma and, with the diarrhoea, CMV and cryptosporidiosis; the initial work-up therefore sends sputum and node material for Xpert MTB/RIF and mycobacterial cultures, HIV viral load, and blood cultures including mycobacterial bottles. Step two is empirical reasoning while cultures incubate: the swinging-to-high pattern with hepatosplenomegaly, pancytopenia and disproportionate alkaline phosphatase keeps MAC live; a lymph node biopsy with AFB staining showing long, beaded bacilli in sheets of macrophages and no M. tuberculosis on molecular testing tilts further. Step three is therapy once confirmed — clarithromycin plus ethambutol at weight-based doses with rifabutin considered, watching ocular toxicity from ethambutol and the cytochrome interactions of rifabutin and clarithromycin with antiretrovirals — plus intensification discussion for severe disease. Step four is the ART conversation: after clinical stabilisation, restart effective ART, since only immune reconstitution cures MAC, and watch for focal nodal IRIS over the following weeks. Step five is the duration discipline and the prophylaxis habit: continue combination therapy for at least a year and until the CD4 is above 100 for six months; when he recovers, the team documents that any future CD4 under 50 re-triggers azithromycin prophylaxis once active disease is excluded.
Where students slip
The commonest error is treating MAC like tuberculosis — quoting a fixed six-month short course or a four-drug rifampicin regimen. The expected answer is a macrolide-ethambutol backbone for at least twelve months with CD4-guided cessation, and rifabutin (not rifampicin) where a rifamycin is used. The second slip is prophylaxis detail: azithromycin once weekly below CD4 50, stopped above 100 for three months — candidates misplace both thresholds or forget that active TB must be excluded first, since prophylaxis given to a TB patient simply delays the diagnosis. Third, students claim person-to-person spread; MAC is environmental, which is why contact screening, so central to TB, has no role here. A quiet viva favourite is why clarithromycin monotherapy fails — rapid mutational resistance within weeks, the same logic as never treating with a single drug.
Frequently asked questions
At what CD4 count does disseminated MAC characteristically occur?
Usually below 50 cells per microlitre, frequently 20-30, reflecting the profound cell-mediated immunity required to contain these environmental mycobacteria.
What regimen treats disseminated MAC?
Clarithromycin 500 mg twice daily (or azithromycin) plus ethambutol 15 mg/kg daily, with rifabutin considered and amikacin or a fluoroquinolone in severe disease — continued for at least twelve months and until the CD4 count is above 100 for six months on ART.
How is MAC diagnosed in the laboratory?
Mycobacterial blood cultures, or culture and histology (AFB-positive macrophages filled with long beaded bacilli) from bone marrow, lymph node or liver; species identification by molecular or biochemical methods distinguishes it from M. tuberculosis.
Which prophylaxis is recommended and when?
Azithromycin 1,200 mg once weekly when the CD4 count is under 50, after excluding active tuberculosis and other mycobacterial disease; it is stopped once the CD4 count exceeds 100 for three months on antiretroviral therapy.
Can MAC spread from patient to patient?
No — MAC organisms live in water and soil and infection is acquired environmentally, so isolation and contact tracing, unlike tuberculosis, have no role in management.